News for Fortress Biotech, Inc. (FBIO)

Fortress Biotech (FBIO) delivered earnings and revenue surprises of 67.09% and 12.58%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

**media[579425]**

Fortress Biotech, Inc. (NASDAQ:FBIO) Q4 2024 Earnings Conference Call March 26, 2025 4:30 PM ETCompany ParticipantsJaclyn Jaffe - Senior Director, Corporate...

Fortress Biotech (FBIO) set to announce FY earnings March 26th. Discover EPS & revenue estimates, historical performance, and key insights.

Fortress Biotech Inc (FBIO) is set to release its Q4 2024 earnings on Mar 26, 2025. The consensus estimate for Q4 2024 revenue is $16.30 million, and the earnin

**media[574688]**

Company to host conference call to discuss financial results and provide a corporate update on March 26, 2025 at 4:30 p.m. ET SCOTTSDALE, Ariz., March 19, 20

FRANKFURT, Germany and MIAMI, March 17, 2025 (GLOBE NEWSWIRE) -- Partex NV and Fortress Biotech, Inc. ( FBIO) (”œFortress”), an innovative biopharmaceutica

**media[568493,568494]**

SCOTTSDALE, Ariz., March 12, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (”œJourney Medical”) ( DERM), a commercial-stage pharmaceutical company t

**media[564363]**

Sun Pharma, India's largest pharmaceutical company, is set to acquire Checkpoint Therapeutics for $355 million. This strategic acquisition will enhanc

Sun Pharma acquires Checkpoint Therapeutics for $355 million, expanding its oncology portfolio with innovative treatments.

PR NewswireMUMBAI, India and WALTHAM, Mass., March 9, 2025 Will add UNLOXCYTâ„¢ (cosibelimab-ipdl), the first and only FDA-approved anti-PD-L1 treatment fo

Sun Pharmaceutical announced the acquisition of Nasdaq-listed Checkpoint Therapeutics, an immunotherapy and oncology company. The deal involves an upfront cash payment of $4.10 per share, totaling up to $355 million, with additional potential payouts based on milestones. The acquisition strengthens Sun Pharma's innovative portfolio in onco-derm therapy, particularly for advanced cutaneous squamous cell carcinoma.

**media[558457]**

U.S. FDA approved Emrosiâ„¢ (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) for the treatment o

WALTHAM, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (”œMustang” or the ”œCompany”) ( MBIO), a clinical-stage biopharmaceutical company f

**media[538133]**